A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood

Nature Protocols

Volumn 2, Issue 4, 2007, Pages 805-810

  Duda, Dan G ^a,b   Cohen, Kenneth S ^b   Scadden, David T ^b   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN;

ARTICLE; CELL COUNT; CELL POPULATION; CELL PROLIFERATION; CELL VIABILITY; CLINICAL PROTOCOL; COMPUTER PROGRAM; CONTROLLED STUDY; CYTOLOGY; DISEASE MARKER; ENDOTHELIUM CELL; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL;

ANTIGENS, CD; BIOLOGICAL MARKERS; CELL COUNT; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HUMANS; PHENOTYPE;

EID: 34248592702     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2007.111     Document Type: Article

References (12)

1. Rafii, S., Lyden, D., Benezra, R., Hattori, K. & Heissig, B. Vascular and haematopoietic stem cells: Novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer 2, 826-835 (2002).
2. Aicher, A. et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med. 9, 1370-1376 (2003).
3. Bertolini, F., Shaked, Y., Mancuso, P. & Kerbel, R.S. The multifaceted circulating endothelial cell in cancer: Towards marker and target identification. Nat. Rev. Cancer 6, 835-845 (2006).
4. Jain, R.K., Duda, D.G., Clark, J.W. & Loeffler, J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3, 24-40 (2006).
5. Monestiroli, S. et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res. 61, 4341-4344 (2001).
6. Mancuso, P. et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97 3658-3661 (2001).
7. Duda, D.G. et al. Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: Implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J. Clin. Oncol. 24, 1449-1453 (2006).
8. Duda, D.G. et al. Reply to: Detection of circulating endothelial cells: CD146-based magnetic separation enrichment or flow cytometric assay? J. Clin. Oncol. 25, e3-e5 (2007).
9. Willett, C.G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10, 145-147 (2004).
10. Willett C.G. et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients. J. Clin. Oncol. 23, 8136-8139 (2005).
11. Batchelor, T.T. et al. AZD2171, a pan-VEGF and PDGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates vasogenic edema in glioblastoma patients. Cancer Cell 11, 83-95 (2007).
12. Rugo, H.S. et al. Change in circulating endothelial cells (CEC) predicts progression free survival (PFS) in patients (pts) with hormone receptor positive metastatic breast cancer (MBC) receiving Letrozole and bevacizumab (ASCO 42). J. Clin. Oncol. 24, 3039 (2006).